



September 2, 2008

Regeneron Announces Webcast Presentation of Results from Phase 2 Study of ARCALYST (R) (rilonacept) in Gout Patients Initiating Urate-Lowering Therapy

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sept. 2, 2008--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Dr. Leonard S. Schleifer, President and Chief Executive Officer of Regeneron, and other members of senior management will host a webcast conference call commencing at 8:30 a.m. Eastern Time on Wednesday, September 3, 2008. Dr. Schleifer will discuss the findings of a Phase 2 study evaluating the efficacy and safety of ARCALYST® (rilonacept) versus placebo in the prevention of gout flares induced by the initiation of uric acid-lowering drug therapy that is used to control gout. A separate press release announcing the study findings will be issued by the Company prior to the conference call. The interactive call can be accessed live through the Regeneron website at www.regeneron.com on the Presentations page of the Investor Relations section. The call, including the question and answer session, can also be accessed by dialing:

Domestic Dial-in Number: (866)314-5050
International Dial-in Number: (617)213-8051
Participant Passcode: 16355081

For those unable to participate during the call, a replay will be available from 10:30 a.m. Eastern Time on September 3, 2008 through October 3, 2008. The call can be accessed by dialing:

Domestic Dial-in Number: (888)286-8010
International Dial-in Number: (617)801-6888
Participant Passcode: 58761816

The replay will be available over the Internet and can be accessed by visiting the Regeneron website at www.regeneron.com on the Presentations page of the Investor Relations section.

Important Information About ARCALYST

ARCALYST is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. IL-1 blockade may interfere with immune response to infections. Serious, life-threatening infections have been reported in patients taking ARCALYST. ARCALYST should be discontinued if a patient develops a serious infection. Taking ARCALYST with tumor necrosis factor inhibitors is not recommended because this may increase the risk of serious infections. Treatment with ARCALYST should not be initiated in patients with active or chronic infections. Patients should not receive a live vaccine while taking ARCALYST. It is recommended that patients receive all recommended vaccinations prior to initiation of treatment with ARCALYST. Patients should be monitored for changes in their lipid profiles and provided with medical treatment if warranted. Hypersensitivity reactions associated with ARCALYST® (rilonacept) administration have been rare. Please see the full Prescribing Information for ARCALYST, available online at www.regeneron.com/ARCALYST-fpi.pdf.

About Regeneron Pharmaceuticals, Inc.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Forward Looking Statement

This news release discusses historical information and includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including Regeneron's

agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ending June 30, 2008. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

CONTACT: Regeneron Pharmaceuticals, Inc.

Investor Relations

914-345-7640

invest@regeneron.com

or

Corporate Communications

Laura Lindsay, 914-345-7800

laura.lindsay@regeneron.com

or

Media Relations

Lauren Tortorete, 212-845-5609

ltortorete@biosector2.com

SOURCE: Regeneron Pharmaceuticals, Inc.